Harrow Health, Inc.
General ticker "HROW" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.2B (TTM average)
Harrow Health, Inc. follows the US Stock Market performance with the rate: 63.4%.
Estimated limits based on current volatility of 3.6%: low 41.63$, high 44.75$
Factors to consider:
- Total employees count: 315 (+45.2%) as of 2023
- Top business risk factors: Profitability concerns, Cybersecurity threats, Regulatory and compliance, Third-party risks, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [24.14$, 51.34$]
- 2025-12-31 to 2026-12-31 estimated range: [19.97$, 43.64$]
Financial Metrics affecting the HROW estimates:
- Negative: with PPE of -121.5 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 4.42
- Negative: Operating cash flow per share per price, % of -1.83 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 17.91 <= 18.93
- Positive: -4.48 < Investing cash flow per share per price, % of -2.74
- Negative: 0.79 < Interest expense per share per price, % of 1.88
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -2.64 <= -0.75
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
Short-term HROW quotes
Long-term HROW plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $88.59MM | $130.19MM | $199.61MM |
| Operating Expenses | $86.68MM | $129.76MM | $190.79MM |
| Operating Income | $1.92MM | $0.43MM | $8.82MM |
| Non-Operating Income | $-15.93MM | $-24.14MM | $-26.14MM |
| Interest Expense | $7.24MM | $21.32MM | $22.79MM |
| R&D Expense | $3.05MM | $6.65MM | $12.23MM |
| Income(Loss) | $-14.01MM | $-23.71MM | $-17.32MM |
| Taxes | $0.07MM | $0.70MM | $0.16MM |
| Profit(Loss)* | $-14.09MM | $-24.41MM | $-17.48MM |
| Stockholders Equity | $27.59MM | $70.77MM | $69.65MM |
| Inventory | $6.54MM | $10.87MM | $10.70MM |
| Assets | $157.38MM | $312.16MM | $388.97MM |
| Operating Cash Flow | $1.71MM | $3.84MM | $-22.20MM |
| Capital expenditure | $7.77MM | $152.55MM | $38.67MM |
| Investing Cash Flow | $-1.74MM | $-152.55MM | $-33.16MM |
| Financing Cash Flow | $54.14MM | $126.53MM | $28.53MM |
| Earnings Per Share** | $-0.51 | $-0.75 | $-0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.